What Are the Game-Changing Growth Opportunities Impacting the Cardiac Biomarkers Diagnostics Industry?
Rising prevalence of cardiovascular disease (CVD) and high sensitivity point-of-care testing (POCT) driving transformational growth in cardiac biomarkers diagnostics
Overview
The global cardiac biomarkers diagnostic industry grows at a significant rate owing to progress propelled by key factors such as the increasing prevalence of CVD, multiplex biomarkers, advancements in diagnostic testing technology, higher adoption rates of POCT, and an intensified focus on preventive healthcare that highlight their essential role in cardiovascular care.
The cardiac biomarkers diagnostics industry is to witness a slight slowdown in growth after 2027, driven by saturation in developed regions, a focus on enhancing the sensitivity and specificity of existing biomarkers rather than creating new ones, the move toward automation in laboratory systems, and improvements in the sensitivity of POCT, limiting reliance on traditional testing and temper market growth.
Even while POCT methods can rapidly access cardiac biomarkers, laboratory-based testing is still required to confirm results, especially when detecting non-ST elevation myocardial infarction (NSTEMI), because the positive predictive value (PPV) using rapid diagnostic algorithms is not ideal. To rule out NSTEMI, recent guidelines recommend using hs-cTnI POCT methods. This helps identify low-risk patients who can be safely discharged without undergoing additional invasive testing.
With a shift toward preventive health, cardiac biomarker screenings are increasingly routine, especially for high-risk individuals. Biomarkers such as NT-proBNP, utilized for early heart failure detection, have become central to routine checkups in regions prioritizing prevention. Japan’s widespread adoption of NT-proBNP in screenings illustrates this trend, leading to increased biomarker demand in Asia-Pacific as countries emphasize early intervention.
- What role do the increasing prevalence of CVD, multiplex biomarkers, advancements in diagnostic testing technology, and higher adoption rates of POCT play in driving innovation and growth in the cardiovascular diagnostics space?
- How does the increasing adoption of NT-proBNP for heart failure detection in routine checkups create growth opportunities in Asia-Pacific?
- How can your team leverage advancements in cardiac biomarker assays to accelerate growth in the diagnostic industry?
Quick links
Click here to download the sample of this analysis
Already a member? Click here to access the analysis
Frost Honorarium Program
Unlock a $1,000 Incentive with a Complimentary Growth Dialog
Engage with our industry experts for a discussion to explore new growth opportunities for your business.
As a token of appreciation, you will receive a $1,000 honorarium—redeemable towards any of our products or services.
Request More Information
Sign up for a complimentary Growth Pipeline Dialog™
A Growth Pipeline Dialog is a structured discussion with our growth experts providing unparalleled technology intelligence and proven implementation best practices. This discussion will spark innovative thinking and help generate a pipeline of growth opportunities you can leverage to maximize your company’s future growth potential.
